Regulatory tracker

The 2026 FDA peptide reclassification, accurately.

Last updated 3 August 2026

Current status: recommended, not approved.

On 23–24 July 2026 an FDA advisory committee voted to recommend that compounding pharmacies be permitted to prepare BPC-157, TB-500 and KPV. The vote is non-binding. No final rule has been published, nothing has been approved, and compounded BPC-157 cannot yet be legally dispensed.

What actually happened

Coverage of this has been unusually poor, so it is worth being precise. Two separate things occurred, and neither is an approval.

In February 2026, Health Secretary Robert F. Kennedy Jr. announced an intention to move roughly 14 of the 19 peptides sitting on the FDA's Category 2 restricted compounding list back to Category 1. In July, the FDA's Pharmacy Compounding Advisory Committee met and voted on seven of them. BPC-157, TB-500 and KPV each passed narrowly, 8 votes to 6 with one abstention — notably against the position of the FDA's own career scientists.

An advisory committee recommendation begins a formal rulemaking process. It does not change the law on the day it happens.

Approval and compounding are different things

	Drug approval	Compounding list
What it means	FDA has reviewed clinical trial data and approved a specific product for a specific use	A licensed pharmacy may prepare the substance for an individual patient with a prescription
Requires clinical trials	Yes	No
Sold as a finished product	Yes	No — prepared per prescription
BPC-157 status	Not approved	Recommended for the list; rulemaking pending

There is no approved BPC-157 drug and this process would not create one. No New Drug Application has been filed and no clinical trial programme has been completed.

Timeline

27 Feb 2026

HHS announcement

Health Secretary Robert F. Kennedy Jr. announced an intention to move roughly 14 of the 19 peptides on the FDA's Category 2 restricted list back to Category 1.

23–24 Jul 2026

Advisory committee vote

The FDA's Pharmacy Compounding Advisory Committee met at White Oak and considered seven peptides. BPC-157, TB-500 and KPV each passed by 8 votes to 6, with one abstention — against the recommendation of the agency's own career scientists.

Proposed rule published

The FDA must publish a proposed rule in the Federal Register. Nothing changes legally until this happens.

Then

Public comment period

Typically 60 to 90 days for public and industry comment on the proposed rule.

Finally

Final determination

The FDA issues a final rule. Legal analysts estimate 12 to 24 months from the advisory vote before legally compounded BPC-157 could reach a pharmacy counter.

Peptides in the group moving back to Category 1

Peptide	What it is	Status
BPC-157	Body Protection Compound-157	Recommended 8–6
TB-500	Thymosin beta-4 fragment	Recommended 8–6
KPV	Alpha-MSH tripeptide fragment	Recommended 8–6
Thymosin Alpha-1	Immune-signalling peptide	In the announced group
CJC-1295	GHRH analogue	In the announced group
Ipamorelin	Ghrelin receptor agonist	In the announced group
AOD-9604	hGH fragment 176-191	In the announced group
GHK-Cu	Copper-binding tripeptide	In the announced group
Selank	Anxiolytic peptide	In the announced group
Semax	Nootropic peptide	In the announced group
MOTS-c	Mitochondrial-derived peptide	In the announced group

The February announcement covered roughly 14 substances. The July committee meeting voted on seven of them; the remainder are expected to follow the same process. Only BPC-157, TB-500 and KPV have recorded committee votes so far.

Peptides remaining restricted

Peptide	What it is
Melanotan II	Melanocortin agonist
GHRP-2	Growth hormone releasing peptide
GHRP-6	Growth hormone releasing peptide
LL-37	Antimicrobial peptide
PEG-MGF	Pegylated mechano growth factor

These were excluded on safety grounds and are not part of the group moving back to Category 1.

What this does not change

Research-grade material is unaffected. Compounding lists govern what licensed pharmacies may prepare for patients. Chemicals supplied for laboratory research are a separate category and remain research materials, not for human consumption.
Nothing is available over the counter. Even after a final rule, compounded preparations require a prescription and a licensed compounding pharmacy.
No efficacy has been established. A compounding listing is not a finding that a substance works. The underlying literature for most of these peptides remains preclinical.

Common questions

Did the FDA approve BPC-157?

No. Nothing has been approved. An FDA advisory committee voted to recommend adding BPC-157 to the list of substances compounding pharmacies may use. That is a non-binding recommendation that starts a rulemaking process, not an approval, and not a final rule.

What is the difference between Category 1 and Category 2?

These are the FDA's groupings for bulk drug substances considered for the 503A compounding list. Category 1 substances may be evaluated for use in compounding. Category 2 substances raise significant safety risks and are effectively barred. Moving from 2 to 1 removes that barrier — it does not by itself authorise anything.

Can I legally buy compounded BPC-157 now?

No. The vote does not place BPC-157 on the 503A Bulks List, and a favourable vote does not legalise compounding. The FDA must publish a proposed rule, take public comment, and issue a final determination first.

How long will the process take?

Legal analysts estimate at least 12 to 24 months from the July 2026 vote before legally compounded BPC-157 could be dispensed. Rulemaking timelines slip routinely, so treat that as a floor rather than a schedule.

Which peptides are staying restricted?

Melanotan II, GHRP-2, GHRP-6, LL-37 and PEG-MGF were not part of the group moving back, on safety grounds.

Does this make BPC-157 an approved drug?

No, and this is the most common misunderstanding. Compounding and drug approval are separate tracks. There is no approved BPC-157 drug — no completed clinical trials, no New Drug Application. Compounding permits a licensed pharmacy to prepare a substance for a specific patient with a valid prescription; it is not approval.

Who would be able to prescribe it?

Any licensed prescriber — MD, DO, NP or PA depending on state scope — writing to a 503A compounding pharmacy. In practice that tends to be functional and integrative medicine, anti-ageing and sports medicine clinics.

Does this change anything about research-grade material?

No. Research chemicals sold for laboratory use are a separate category entirely and are unaffected by the compounding lists. Material supplied for research remains research material and is not for human consumption.

Reporting this page draws on

This page tracks a live regulatory process and is updated as it moves. It is informational, not legal advice. Everything we supply is for laboratory research use only.